Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Treasury Shares: 2014-2025

Historic Treasury Shares for Myriad Genetics (MYGN) over the last 11 years, with Sep 2025 value amounting to $7.5 million.

  • Myriad Genetics' Treasury Shares rose 44.23% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 44.23%. This contributed to the annual value of $5.3 million for FY2024, which is 20.45% up from last year.
  • Latest data reveals that Myriad Genetics reported Treasury Shares of $7.5 million as of Q3 2025, which was down 1.32% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Treasury Shares registered a high of $7.6 million during Q2 2025, and its lowest value of $3.1 million during Q4 2021.
  • Moreover, its 3-year median value for Treasury Shares was $5.2 million (2024), whereas its average is $5.5 million.
  • Per our database at Business Quant, Myriad Genetics' Treasury Shares skyrocketed by 78.95% in 2021 and then decreased by 8.93% in 2025.
  • Over the past 5 years, Myriad Genetics' Treasury Shares (Quarterly) stood at $3.1 million in 2021, then climbed by 19.35% to $3.7 million in 2022, then rose by 18.92% to $4.4 million in 2023, then grew by 20.45% to $5.3 million in 2024, then spiked by 44.23% to $7.5 million in 2025.
  • Its Treasury Shares stands at $7.5 million for Q3 2025, versus $7.6 million for Q2 2025 and $5.1 million for Q1 2025.